These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7569150)

  • 1. [Double-blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of continuous therapy with estradiol valerate and medroxyprogesterone acetate].
    Blümel JE; Roncagliolo ME; Gramegna G; Vásquez R; Estartus A; Tacla X; Brandt A
    Rev Chil Obstet Ginecol; 1994; 59(5):354-60. PubMed ID: 7569150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
    Saure A; Planellas J; Poulsen HK; Jaszczak P
    Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.
    Bhathena RK; Anklesaria BS; Ganatra AM; Pinto R
    Br J Clin Pharmacol; 1998 Feb; 45(2):170-2. PubMed ID: 9491833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens.
    Heikkinen JE; Vaheri RT; Ahomäki SM; Kainulainen PM; Viitanen AT; Timonen UM
    Am J Obstet Gynecol; 2000 Mar; 182(3):560-7. PubMed ID: 10739508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of bone loss by estradiol valerate combined with medroxyprogesterone acetate among postmenopausal women with osteopenia].
    Lu J; Lin S; Zhang L; Yu W; Shen Y; Zhang Y; Chen F
    Zhonghua Yi Xue Za Zhi; 2002 Dec; 82(23):1593-8. PubMed ID: 12667363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
    Langer RD; Landgren BM; Rymer J; Helmond FA;
    Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
    Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
    Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
    Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
    J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
    Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
    Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone.
    Chen FP; Lee N; Soong YK
    J Reprod Med; 1998 Jul; 43(7):568-74. PubMed ID: 9693406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy.
    Cano A; Tarín JJ; Dueñas JL
    Fertil Steril; 1999 Jan; 71(1):129-36. PubMed ID: 9935129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of antiandrogens in hormone replacement therapy.
    Schneider HP
    Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.
    Thromb Haemost; 1996 Mar; 75(3):476-80. PubMed ID: 8701411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
    Hargrove JT; Maxson WS; Wentz AC; Burnett LS
    Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women.
    Koivu TA; Dastidar P; Jokela H; Nikkari ST; Jaakkola O; Koivula T; Punnonen R; Lehtimäki T
    Atherosclerosis; 2001 Aug; 157(2):471-9. PubMed ID: 11472749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
    Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
    Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E; Mälkönen M; Manninen V
    N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
    Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
    BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.